Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Hormone. University of California San Francisco, San Francisco, California, United States

Survival: 16.7 months
Toxicity Grade: 4
Treatments: Hormone
Country: United States
City/State/Province: San Francisco, California
Hospital: University of California San Francisco
Journal: Link
Date: 9/2004

Patients: This Phase III trial involved a total of 260 patients with hormone refractory (androgen independent) prostate cancer. Patients were divided into two groups: Group 1 with 132 patients and Group 2 with 128 patients. The median age for patients in Group 1 was 71 years. For both groups, the median PSA was 58 years.

Treatment: Patients in Group 1 underwent anti-androgen withdrawal only.

Toxicity: For patients in Group 1 the only grade 3-4 toxicity was hepatic (presumably attributed to causes other than the anti-androgen withdrawal itself).

Results: For patients in Group 1 the median survival was 16.7 months.

Support: Support was provided by Janssen Pharmaceutica Products. This company markets ketoconazole under the brand name nizoral.

Correspondence: Eric J. Small, MD

E-mail to a Friend Email Physician More Information